Hence, therapies against both MM cells and microenvironment control, such as daratumab, an antibody drug against CD38 that induces antibody-dependent cytotoxic events in CD38-expressing cancer cells and complement-dependent cytotoxicity [50,51,52], show success in MM treatment [53]. This evidence concerns the gene CD38 and Miyoshi myopathy.